Published 16 hours ago • loading... • Updated 8 hours ago

Antengene Expands XPOVIO® Indications in Malaysia with Approval in Diffuse Large B-cell Lymphoma

On Dec. 16, 2025, Antengene announced the Malaysian NPRA approved a supplemental NDA for XPOVIO to treat adult patients with relapsed or refractory DLBCL after at least 2 lines who are ineligible for autologous stem cell transplant.
Already approved in ten APAC countries, XPOVIO expands its Malaysia portfolio to three indications across multiple myeloma and DLBCL, building on prior Malaysian approvals for MM combinations.
As a commercial-stage biotech, Antengene continues advancing preclinical and clinical assets, with 32 investigational new drug approvals and a pipeline including ATG-022, ATG-037, ATG-101, ATG-031, and ATG-042.
For patients in Malaysia, the approval provides a new treatment option, and Antengene expects XPOVIO to receive public insurance coverage in more APAC markets, benefiting a broader population.
Antengene cautioned that its intentions are as of the article date and warned actual future results may differ, directing readers to the Company's Annual Report for the year ended December 31, 2024 and Hong Kong Stock Exchange filings for risks.

Insights by Ground AI

42 Articles

LoudounTimes.com

+41 Reposted by 41 other sources

Center

Antengene Expands XPOVIO® Indications in Malaysia with Approval in Diffuse Large B-cell Lymphoma

SHANGHAI and HONG KONG, Dec. 16, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies…

16 hours ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year